Health & Medical Archives | Page 18 of 242 | Be Korea-savvy

Archive by category Health & Medical

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC

SHANGHAI, June 25, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab (product code: JS001) in [...]

OPEN Health and Fusion Announce Partnership to Deliver AI-powered Healthcare Communications

OPEN Health and Fusion Announce Partnership to Deliver AI-powered Healthcare Communications

London, UK, June 24, 2024 (Korea Bizwire) – OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine learning (ML) solutions provider that will work exclusively with OPEN Health. This alliance will see fusion’s market-leading AI capabilities deployed across OPEN Health’s [...]

Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa

Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South Africa. EXBLIFEP® has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of severe infections earlier in 2024. Saint-Louis, France and Weil am Rhein, Germany and Zurich, [...]

KFSHRC Successfully Produces the First Therapeutic T-Cells in the Kingdom

KFSHRC Successfully Produces the First Therapeutic T-Cells in the Kingdom

Treatment Costs Reduced by around 80% and Accelerated Access to Treatment RIYADH, Saudi Arabia, June 23, 2024 (Korea Bizwire) – King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully produced CAR T-cells internally for cancer treatment. This breakthrough has reduced the cost of treatment from 1.3 million SAR to approximately 250,000 SAR per treatment, [...]

Novotech Liver Cancer Research Landscape Report Finds 1,700 Trials Initiated Globally

Novotech Liver Cancer Research Landscape Report Finds 1,700 Trials Initiated Globally

BOSTON, June 22, 2024 (Korea Bizwire) – Novotech, a global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to expedite the development of cutting-edge therapeutics across all phases, has today published a leading industry report, Liver Cancer – Global Clinical Trial Landscape. Liver cancer is the sixth most diagnosed cancer worldwide and the [...]

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data

BOSTON, June 21, 2024 (Korea Bizwire) – Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has today released a key research whitepaper entitled Antibody-drug conjugates – Global Clinical Trial Landscape. Novotech’s whitepaper examines how the antibody-drug conjugates (ADCs), [...]

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging or previously undruggable disease targets Financing led by 3E Bioventures Capital and Proxima Ventures Ltd. with participation from Lapam Capital Founded by Professor Jun O. Liu of Johns Hopkins University School of Medicine, a pioneer in the molecular [...]

Philips Completes Cancellation of 4.4 Million Shares

Philips Completes Cancellation of 4.4 Million Shares

June 19, 2024, Amsterdam, the Netherlands (Korea Bizwire) – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips’ current issued [...]

Future Health Index 2024 Global Report: Healthcare Leaders Turn to AI to Address Critical Gaps in Patient Care

Future Health Index 2024 Global Report: Healthcare Leaders Turn to AI to Address Critical Gaps in Patient Care

Healthcare leaders indicate automation is crucial in addressing staff shortages, but staff remain skeptical Interest in Generative AI grows, with majority of health leaders investing in, or planning to invest in AI technologies to help reduce delays in patient care June 18, 2024, Amsterdam, the Netherlands (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global [...]

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

SHANGHAI, June 18, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab (product code: JS001) in [...]